Asset profile
dupilumab · Dupixent
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Atopic Dermatitis, Asthma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
126 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Dupilumab (Dupixent): this drug | Approved | Monoclonal antibody | IL-4R-alpha | ||
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| CKD-706 | Phase 1 | Monoclonal antibody | IL-4R-alpha | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 |
…and 111 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(37 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
October 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-10-07 · NCT02612454 · CT.gov ↗
What to watch
November 2026 (1)
Phase 2AsthmaActive not recruiting
Est. primary completion 2026-11-01 · NCT05720325 · CT.gov ↗
What to watch
December 2026 (4)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2026-12 · NCT05268107 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Hypereosinophilic SyndromeRecruiting
Est. primary completion 2026-12-30 · NCT06477653 · CT.gov ↗
What to watch
Phase 2AsthmaActive not recruiting
Est. primary completion 2026-12-31 · NCT05347771 · CT.gov ↗
What to watch
2027 (18)
January 2027 (3)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-01 · NCT03694158 · CT.gov ↗
What to watch
Early phase / not applicableAtopic DermatitisRecruiting
Est. primary completion 2027-01 · NCT06182436 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
March 2027 (2)
April 2027 (3)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-04-01 · NCT06116526 · CT.gov ↗
What to watch
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-04-24 · NCT06572228 · CT.gov ↗
What to watch
Phase 4Atopic DermatitisActive not recruiting
Est. primary completion 2027-04-29 · NCT05983068 · CT.gov ↗
What to watch
June 2027 (4)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-06 · NCT05042258 · CT.gov ↗
What to watch
Phase 2Atopic DermatitisRecruiting
Est. primary completion 2027-06-30 · NCT07330934 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Food AllergyActive not recruiting
Est. primary completion 2027-08-31 · NCT06369467 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Prurigo NodularisRecruiting
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2027-11-30 · NCT05551793 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1Eosinophilic Esophagitis (EoE)Enrolling by invitation
Est. primary completion 2027-12 · NCT07358234 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
2028 (7)
February 2028 (2)
June 2028 (1)
Phase 3Eosinophilic Esophagitis (EoE)Recruiting
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Chronic Obstructive Pulmonary Disease (COPD)Not yet recruiting
Est. primary completion 2028-07-30 · NCT07587658 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3AsthmaEnrolling by invitation
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-12-23 · NCT07053423 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, Liver MetastasesRecruiting
Est. primary completion 2028-12-31 · NCT07277322 · CT.gov ↗
What to watch
2029 (2)
2030 (2)
2031 (1)
June 2031 (1)
Phase 1Skin DiseasesRecruiting
Est. primary completion 2031-06-30 · NCT05649098 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Early phase / not applicableRhinosinusitis Chronic, Nasal PolypsRecruiting
Est. primary completion 2034-09-02 · NCT06501807 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.